0000000000810817

AUTHOR

Torben Biester

showing 3 related works from this author

Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes (VibRate): A multinational prospective observat…

2021

While data on the efficacy and safety of continuous glucose monitoring (CGM) exist across a broad age spectrum, it is limited in very young children with type 1 diabetes (T1D). We aimed to assess real-world data in this high-risk population, focusing on glycemic variability and metrics beyond HbA1c. A 12-month multi-national, prospective, observational, registry-based cohort study in children with T1D aged 1-7 years compared glucose control using real-time CGM and using fingerstick blood glucose monitoring (BGM) alone. The prespecified primary endpoint was a difference in coefficient of variation (CV) between the CGM users and BGM-only cohort. Among 227 individuals using insulin pumps (42% …

Insulin pumpBlood GlucosePediatricsmedicine.medical_specialtyendocrine system diseasesFingerstickEndocrinology Diabetes and MetabolismPopulationChildren; Continuous glucose monitoring; Insulin pump; Toddlers; Type 1 diabetesCohort StudiesHDE END PEDEndocrinologyInsulin Infusion SystemsInternal MedicinemedicineHumansHypoglycemic AgentsInsulinInsulin pumpeducationChildChildrenContinuous glucose monitoringchildren; continuous glucose monitoring; insulin pump; toddlers; type 1 diabetesGlycemicBlood glucose monitoringGlycated HemoglobinToddlerseducation.field_of_studyType 1 diabetesmedicine.diagnostic_testEndocrinology; Metabolismbusiness.industryBlood Glucose Self-Monitoringnutritional and metabolic diseasesDiabetes type 1medicine.diseaseType 1 diabetesDiabetes Mellitus Type 1GlucoseChild PreschoolCohortbusinessCohort studyDiabetes Obesity & Metabolism
researchProduct

The automated pancreas: A review of technologies and clinical practice

2021

Insulin pumps and glucose sensors are effective in improving diabetes therapy and reducing acute complications. The combination of both devices using an algorithm-driven interoperable controller makes automated insulin delivery (AID) systems possible. Many AID systems have been tested in clinical trials and have proven safety and effectiveness. However, currently, none of these systems are available for routine use in children younger than 6 years in Europe. For continued use, both users and prescribers must have sound knowledge of the features of the individual AID systems. Presently, all systems require various user interactions (e.g. meal announcements) because fully automated systems ar…

Pancreas ArtificialInsulin pumpTelemedicinebusiness.industryBlood Glucose Self-MonitoringEndocrinology Diabetes and MetabolismInteroperabilityHCL; artificial pancreas; automated delivery; closed loop; insulin; insulin AIDCloud computingDiabetes TherapyArtificial pancreasClinical trialInsulin Infusion SystemsEndocrinologyRisk analysis (engineering)Diabetes MellitusInternal MedicineHumansMedicineMetric (unit)ChildbusinessDiabetes, Obesity and Metabolism
researchProduct

Proceedings of 21st ISPAD science school for physicians 2022.

2022

SchoolsEndocrinology Diabetes and MetabolismPhysiciansPediatrics Perinatology and Child HealthInternal MedicineHumansPractice Patterns Physicians'Societies MedicalPediatric diabetesREFERENCES
researchProduct